摘要
目的探讨慢性前列腺炎患者应用盐酸坦索罗辛治疗的临床效果。方法80例慢性前列腺炎患者,根据随机数字表法分为对照组与观察组,每组40例。对照组单独应用左氧氟沙星治疗,观察组实施左氧氟沙星+盐酸坦索罗辛治疗。比较两组患者治疗效果以及治疗前后美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)评分、尿动力学指标[排尿量、最大尿流率(MFR)、平均尿流率(AFR)]、症状评分(疼痛与不适评分、症状对生活质量的影响评分、排尿症状评分、症状严重程度评分)、视觉模拟评分法(VAS)评分。结果观察组患者治疗总有效率95.00%高于对照组的80.00%,差异具有统计学意义(P<0.05)。治疗后,两组患者NIH-CPSI评分均低于治疗前,且观察组患者NIH-CPSI评分(4.73±0.37)分低于对照组的(13.29±3.19)分,差异具有统计学意义(P<0.05)。治疗后,两组患者排尿量、MFR、AFR均高于治疗前,且观察组患者排尿量(467.79±32.15)ml/d、MFR(27.57±2.39)ml/s、AFR(18.81±2.10)ml/s均高于对照组的(371.36±40.07)ml/d、(23.43±2.21)ml/s、(15.49±1.58)ml/s,差异具有统计学意义(P<0.05)。治疗后,两组患者疼痛与不适评分、症状对生活质量的影响评分、排尿症状评分、症状严重程度评分均低于治疗前,且观察组患者疼痛与不适评分(5.29±0.58)分、症状对生活质量的影响评分(1.88±0.28)分、排尿症状评分(1.48±0.25)分、症状严重程度评分(6.76±1.21)分均低于对照组的(9.21±1.06)、(2.50±0.37)、(1.96±0.30)、(11.16±1.37)分,差异具有统计学意义(P<0.05)。治疗后,两组患者VAS评分均低于治疗前,且观察组患者VAS评分(2.14±0.73)分低于对照组的(4.10±0.81)分,差异具有统计学意义(P<0.05)。结论慢性前列腺炎患者应用左氧氟沙星+盐酸坦索罗辛治疗的临床效果突出,不仅对患者疼痛和相关临床症状具备改善作用,同时可降低NIH-CPSI评分,值得临床推广。
Objective To discuss the clinical effect of tamsulosin hydrochloride in the treatment of patients with chronic prostatitis.Methods A total of 80 patients with chronic prostatitis were divided into the control group and the observation group according to the random numerical table,with 40 cases in each group.The control group was treated with levofloxacin alone,and the observation group was treated with levofloxacin+tamsulosin hydrochloride.Both groups were compared in terms of therapeutic effect,National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI)score,urodynamic index[urine output,maximum flow rate(MFR),average flow rate(AFR)],symptom score(pain and discomfort score,symptom impact on quality of life score,urinary symptom score,symptom severity score),and visual analogue scale(VAS)score.Results The total effective rate of the observation group was 95.00%,which was higher than that of 80.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,NIH-CPSI score in both groups was lower than that before treatment in this group,and the NIH-CPSI score of(4.73±0.37)points in the observation group was lower than that of(13.29±3.19)points in the control group.The differences were statistically significant(P<0.05).After treatment,the urine output,MFR and AFR in both groups were higher than those before treatment in this group;the observation group had urinary output of(467.79±32.15)ml/d,MFR of(27.57±2.39)ml/s and AFR of(18.81±2.10)ml/s,which were higher than those of(371.36±40.07)ml/d,(23.43±2.21)ml/s and(15.49±1.58)ml/s in the control group;the differences were statistically significant(P<0.05).After treatment,the pain and discomfort score,symptom impact on quality of life score,urinary symptom score,symptom severity score in both groups were lower than those before treatment in this group;in the observation group,the pain and discomfort score was(5.29±0.58)points,the symptom impact on quality of life score was(1.88±0.28)points,the urinary symptom score
作者
刘金光
田秀秀
LIU Jin-guang;TIAN Xiu-xiu(Department of Surgery,Dongchangfu District Hospital of Traditional Chinese Medicine,Liaocheng 252000,China)
出处
《中国实用医药》
2023年第21期41-44,共4页
China Practical Medicine
